Cancer Biomarker Market to Reach US$ 62.49 Billion by 2033 at ~9.0% CAGR; Rising Cancer Incidence and Precision Oncology Drive Growth

The global Cancer Biomarker Market reached US$ 28.62 billion in 2024 and is expected to reach US$ 62.49 billion by 2033, growing at a CAGR of approximately 9.0% during the forecast period 2025-2033. Market growth is driven by rising cancer incidence worldwide, increasing demand for early and accurate cancer diagnosis, and expanding adoption of precision oncology approaches that utilize biomarkers for targeted treatment selection and monitoring.

Cancer biomarkers are measurable biological molecules-such as DNA, RNA, proteins, or metabolites-found in blood, tissues, or other bodily fluids, that indicate the presence, progression, or therapeutic response of cancer. These biomarkers are widely used in risk assessment, early detection, prognosis determination, and monitoring of treatment effectiveness. Technological advancements in molecular diagnostics, next-generation sequencing (NGS), and bioinformatics are enhancing biomarker discovery and clinical utility. Growing investments in cancer research, expansion of companion diagnostics, and broader integration of personalized medicine strategies across healthcare systems are further supporting sustained growth in the cancer biomarker market.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/cancer-biomarkers-market?sai-v
The Cancer Biomarker Market refers to the global industry focused on the discovery, development, and commercialization of biological markers used for cancer detection, prognosis, treatment selection, and disease monitoring.

Key Developments
✅ January 2026: In North America, adoption of AI-driven cancer biomarker panels increased in clinical labs to enhance early detection and personalized treatment planning.

✅ December 2025: In Europe, precision oncology programs expanded use of liquid biopsy tests for monitoring minimal residual disease and therapy response.

✅ November 2025: In Asia-Pacific, cancer centers reported rising utilization of multi-omics biomarker assays to support targeted therapies in breast and lung cancers.

✅ October 2025: In Latin America, oncology clinics increased deployment of predictive biomarker testing for immunotherapy eligibility assessments.

✅ September 2025: In the Middle East, healthcare systems strengthened genomic profiling initiatives to integrate cancer biomarker data into national cancer registries.

✅ August 2025: In Africa, pilot programs for affordable point-of-care biomarker tests were introduced to improve access in resource-limited oncology settings.

Mergers & Acquisitions
✅ January 2026: In North America, a global diagnostics company acquired a liquid biopsy biomarker startup to broaden its precision oncology portfolio.

✅ December 2025: In Europe, a leading biotech firm acquired a companion diagnostic developer specializing in predictive cancer biomarkers to support targeted therapy pipelines.

✅ November 2025: In Asia-Pacific, a regional healthcare investor completed the acquisition of a molecular diagnostics provider focused on cancer biomarker panels to accelerate market reach.

Key Players
F. Hoffmann-La Roche Ltd | Thermo Fisher Scientific, Inc. | QIAGEN N.V. | Illumina, Inc. | Bio-Rad Laboratories, Inc. | Abbott Laboratories | bioMérieux SA | Enzo Biochem, Inc. | Merck Millipore | Micron Technology

Key Highlights
F. Hoffmann-La Roche Ltd - Holds 18.7% share, driven by strong leadership in oncology diagnostics, companion diagnostics development, and extensive adoption of biomarker-based cancer testing.

Thermo Fisher Scientific, Inc. - Holds 16.9% share, supported by comprehensive cancer biomarker workflows, molecular diagnostics platforms, and strong presence across research and clinical laboratories.

QIAGEN N.V. - Holds 13.8% share, benefiting from expertise in sample preparation, molecular assays, and integration of biomarker testing with PCR and sequencing technologies.

Illumina, Inc. - Holds 12.6% share, driven by dominance in next-generation sequencing platforms used for genomic cancer biomarker discovery and precision oncology.

Abbott Laboratories - Holds 9.4% share, supported by a broad diagnostics portfolio including immunoassays and molecular tests for oncology applications.

Bio-Rad Laboratories, Inc. - Holds 8.1% share, focused on specialty cancer diagnostics, digital PCR technologies, and biomarker validation tools.

bioMérieux SA - Holds 6.2% share, leveraging strengths in molecular diagnostics and infectious disease platforms adapted for oncology biomarker testing.

Merck Millipore - Holds 5.4% share, providing critical reagents, assay components, and biomarker research tools for cancer diagnostics and drug development.

Enzo Biochem, Inc. - Holds 3.1% share, focused on niche molecular diagnostic kits and biomarker research solutions for oncology applications.

Micron Technology - Holds 2.8% share, contributing through advanced memory and storage solutions supporting high-throughput genomic and biomarker data processing.

Purchase this report before year-end and unlock an exclusive 30% discount: https://www.datamintelligence.com/buy-now-page?report=cancer-biomarkers-market?sai-v
(Purchase 2 or more Reports and get 50% Discount)

Market Drivers
- Rising global cancer incidence increasing demand for early detection, diagnosis, and disease monitoring solutions.

- Growing adoption of personalized and precision oncology approaches utilizing biomarkers for targeted therapy selection.

- Advancements in genomics, proteomics, and molecular diagnostics improving biomarker discovery and clinical validation.

- Increasing use of biomarkers in drug development and clinical trials to enhance treatment efficacy and patient stratification.

- Expansion of screening programs and awareness initiatives promoting early cancer diagnosis and biomarker testing.

Industry Developments
- Continuous development of novel genomic, proteomic, and liquid biopsy-based cancer biomarkers.

- Rising integration of biomarkers into companion diagnostics to support targeted and immuno-oncology therapies.

- Strategic collaborations between diagnostic companies, pharmaceutical firms, and research institutions to accelerate biomarker commercialization.

- Expansion of high-throughput testing platforms and automation to support large-scale biomarker analysis.

- Increased adoption of AI and bioinformatics tools for biomarker data analysis and clinical decision support.

Regional Insights
North America - 38% share: "Driven by advanced oncology research infrastructure, high adoption of precision medicine, strong reimbursement frameworks, and widespread use of companion diagnostics."

Europe - 27% share: "Supported by established cancer screening programs, strong academic research base, and growing use of biomarkers in clinical oncology."

Asia Pacific - 29% share: "Fueled by rising cancer burden, expanding diagnostic infrastructure, increasing healthcare investments, and growing adoption of molecular testing."

Latin America - 4% share: "Driven by improving cancer diagnostic capabilities, expanding private laboratory networks, and increasing awareness of early detection."

Middle East & Africa - 2% share: "Supported by gradual development of oncology diagnostics, rising healthcare investments, and increasing focus on early cancer diagnosis."

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/cancer-biomarkers-market?sai-v

Key Segments

By Cancer Indication
Breast cancer represents a major segment, driven by high prevalence and extensive use of biomarker-based testing for early detection and treatment selection. Lung cancer holds a significant share, supported by rising incidence rates and growing adoption of molecular and genetic profiling. Colorectal cancer contributes notably due to increasing screening programs and biomarker-guided therapy approaches. Cervical cancer applications are growing steadily, driven by improved diagnostic initiatives and HPV-related biomarker testing. Sarcoma represents a smaller but important segment, supported by advances in precision oncology and targeted diagnostics.

By Biomarker Type
Protein biomarkers dominate the market, driven by their established role in diagnostics, disease monitoring, and treatment response evaluation. Genetic biomarkers are witnessing rapid growth, supported by advancements in genomics, next-generation sequencing, and personalized medicine. Other biomarker types contribute through emerging and complementary diagnostic approaches.

By Profiling Technology
Omics technologies hold a substantial share, driven by their ability to provide comprehensive molecular insights and support precision medicine. Cytogenetics contributes significantly through chromosomal and structural variation analysis. Immunoassays remain widely used due to their reliability, scalability, and cost-effectiveness. Imaging technologies support biomarker-driven visualization and disease assessment, while bioinformatics is growing rapidly, driven by increasing data volumes and the need for advanced analytics and interpretation.

By Application
Drug discovery and development represent a leading application segment, driven by increasing investment in targeted therapies and biomarker-driven R&D. Disease screening and diagnosis hold a significant share, supported by early detection initiatives and preventive healthcare programs. Treatment planning and risk assessment are expanding steadily due to growing adoption of personalized treatment strategies. Other applications contribute through clinical research and companion diagnostics.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.